Synthesis

An efficient synthesis of nilotinib (AMN107)

WS Huang, WC Shakespeare

Index: Huang, Wei-Sheng; Shakespeare, William C. Synthesis, 2007 , # 14 p. 2121 - 2124

Full Text: HTML

Citation Number: 31

Abstract

Imatinib (also called Gleevec, STI571), a Bcr-Abl tyrosine kinase inhibitor developed by Novartis, has been the first-line treatment for patients with chronic myelogenous leukemia (CML) since 2001. [1] Most newly diagnosed CML patients with chronic phase disease treated with Imatinib achieve durable response; however, relapses have been observed in most patients with more advanced disease. Mutations in the Bcr-Abl gene are the most common cause ...